Get the Stockscreener App
51.21
2.64%
-1.39
After Hours:
51.21
Bridgebio Pharma Inc stock is traded at $51.21, with a volume of 2.09M.
It is down -2.64% in the last 24 hours and up +4.32% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$52.60
Open:
$52.91
24h Volume:
2.09M
Relative Volume:
0.75
Market Cap:
$9.79B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-21.25
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-4.07%
1M Performance:
+4.32%
6M Performance:
+57.13%
1Y Performance:
+90.02%
1-Day Range:
$51.03
$54.29
1-Week Range:
$51.03
$54.60
52-Week Range:
$21.72
$54.60
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
51.21 | 10.12B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma stock price target raised to $82 from $72 at UBS - Investing.com Canada
BBIO Stock: UBS Raises Price Target Amidst Continued Buy Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Challenges Pfizer's ATTR-CM Promotion Tactics - GuruFocus
Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha
Fred Alger Management LLC Invests $982,000 in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Alliancebernstein L.P. Has $92.79 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
UBS Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Baird Financial Group Inc. Acquires Shares of 41,326 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Adage Capital Partners GP L.L.C. Purchases 246,555 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Philosophy Capital Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com
BridgeBio stock maintains Buy rating at UBS ahead of key trial data - Investing.com Canada
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $58 to $76 - 富途牛牛
BridgeBio Pharma, Inc. $BBIO Shares Sold by Woodline Partners LP - MarketBeat
Zimmer Partners LP Buys 121,000 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bosun Asset Management LLC Takes $412,000 Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Sold by Exome Asset Management LLC - MarketBeat
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential - TipRanks
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Director Sells $3,933,840.00 in Stock - MarketBeat
238,168 Shares: BridgeBio Pharma's Major Employee Stock Grants Signal Growth Push in Genetic Disease Research - Stock Titan
BridgeBio Pharma stock maintains Buy rating at Jefferies on encaleret potential - Investing.com Canada
Transcript : BridgeBio Pharma, Inc.Special Call - MarketScreener
Cutter Capital Management LP Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
Cormorant Asset Management LP Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock By Investing.com - Investing.com South Africa
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock - Investing.com
Will BridgeBio Pharma Inc. benefit from government policyPortfolio Risk Report & High Conviction Trade Alerts - classian.co.kr
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $68 - 富途牛牛
BridgeBio Pharma Inc. Price Holds Above Key Fib Level2025 Year in Review & Risk Adjusted Swing Trade Ideas - beatles.ru
BridgeBio’s Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial - Endpoints News
BridgeBio Pharma (BBIO): Assessing Valuation After Strong Encaleret Data and Pipeline Advances - Yahoo Finance
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact - TipRanks
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $70.00 - MarketBeat
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment By Investing.com - Investing.com Nigeria
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment - Investing.com India
BridgeBio Pharma Inc. recovery potential after sell offJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
BridgeBio Pharma Reports Promising Phase 2 Results for Encaleret in Post-Surgical Hypoparathyroidism, Plans Registrational Study for 2026 - Quiver Quantitative
Encaleret Showed Parathyroid Hormone-Independent - GlobeNewswire
BridgeBio Pharma says intends to initiate registrational clinical study of Encaleret in 2026 - MarketScreener
80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study - Stock Titan
Chart based analysis of BridgeBio Pharma Inc. trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
Why is BridgeBio Pharma Inc. stock going down2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک
HBK Investments L P Invests $519,000 in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Is BridgeBio Pharma Inc. stock a top performer YTDAnalyst Downgrade & Real-Time Market Trend Scan - خودرو بانک
BridgeBio Pharma stock hits 52-week high at $52.85 By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Panagora Asset Management Inc. - MarketBeat
BridgeBio Pharma Inc. stock momentum explainedJuly 2025 Action & Smart Allocation Stock Tips - Newser
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):